17:14 , Dec 27, 2016 |  BC Week In Review  |  Clinical News

BTI320: Ph II SG01 data

Top-line data from the double-blind, Chinese Phase II SG01 trial in 60 high-risk prediabetes patients who are otherwise healthy showed that thrice-daily 4 and 8 g oral doses of BTI320 for 16 weeks were well...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Financial News

Boston Therapeutics completes private placement of convertible notes and warrants

Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H.   Business: Chemistry, Endocrine/Metabolic, Other   Date completed: 2016-10-03   Type: Private placement of convertible notes and warrants   Raised: $1.6 million   Shares outstanding prior: 44.3 million  ...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Financial News

Boston Therapeutics withdraws best efforts offering

Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H.   Business: Chemistry, Endocrine/Metabolic, Other   Date announced: 2016-07-13   Type: Best efforts offering   Note: Boston Therapeutics withdrew its self-underwritten, best efforts offering.  ...
07:00 , May 4, 2015 |  BC Week In Review  |  Financial News

Boston Therapeutics amends best efforts offering

Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H.   Business: Endocrine/Metabolic, Inflammation, Chemistry   Date announced: 2015-04-28   Type: Best efforts offering   To be raised: Up to $5 million   Shares: 25 million   Price prior:...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Financial News

Boston Therapeutics proposes best efforts offering

Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H.   Business: Endocrine/Metabolic, Inflammation, Chemistry   Date announced: 2014-08-15   Type: Best efforts offering   To be raised: Up to $3 million   Shares: 6.5 million   Price prior:...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Clinical News

BTI-320: Phase IIb data

Top-line data from the double-blind, placebo-controlled, 3-way crossover, U.S. Phase IIb SD-002 trial in 23 Type II diabetics on a stable dose of daily metformin showed that 8 patients responded to BTI-320 with up to...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

BTI-320: Completed Phase IIb enrollment

Boston Therapeutics completed enrollment of 24 Type II diabetics who are being treated with metformin in the double-blind, placebo-controlled, 3-way crossover, U.S. Phase IIb SD-002 trial evaluating BTI-320 for 3 months. Boston Therapeutics Inc. (OTCQB:BTHE),...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Boston Therapeutics Inc management update

Boston Therapeutics Inc . (OTCQB:BTHE), Manchester, N.H.   Business: Endocrine/Metabolic, Inflammation, Chemistry   Hired: Benjamin Rivnay as chief scientist, a newly created position, formerly director of R&D at Formatech Inc.  ...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Clinical News

BTI-320: Phase II start

This month, Boston Therapeutics will begin a double-blind, placebo-controlled, 3-way crossover, U.S. Phase II trial to evaluate BTI-320 for 3 months in 24 Type II diabetics who are being treated with metformin. Boston Therapeutics Inc....
08:00 , Nov 18, 2013 |  BC Week In Review  |  Clinical News

PAZ320: Phase IIb started

Boston Therapeutics began a double-blind, placebo-controlled, French Phase IIb trial to evaluate PAZ320 in 24 Type II diabetics being treated with metformin. Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H.   Product: PAZ320   Business: Endocrine/Metabolic  ...